comparemela.com
Home
Live Updates
Preventing Clinically Meaningful Progression - Breaking News
Pages:
Latest Breaking News On - Preventing clinically meaningful progression - Page 1 : comparemela.com
Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA
Oral APX3330 Achieved Statistical Significance on a Key Pre-specified Secondary Endpoint of Preventing Clinically Meaningful Progression of Diabetic Retinopathy after 24 Weeks of Treatment Oral. | January 25, 2023
Bret shapiro
Corey davis
Ocuphire pharma
Mina sooch
Peterk kaiser
Early treatment diabetic retinopathy study research group
Macula society annual meeting
Cole eye institute
Cleveland clinic foundation
Globenewswire inc
Ocuphire pharma inc
Statistical significance
Key pre specified secondary endpoint
Preventing clinically meaningful progression
Diabetic retinopathy
Favorable safety
vimarsana © 2020. All Rights Reserved.